Ekso Bionics Holdings, Inc. (EKSO) Insider Trading Activity

NASDAQ$9.87
Market Cap
$25.88M
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
560 of 888
Rank in Industry
30 of 49

EKSO Insider Trading Activity

EKSO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$232,062
6
100

Related Transactions

Wong JeromeChief Financial Officer
0
$0
2
$60,001
$-60,001
Jones Jason CChief Operating Officer
0
$0
3
$60,149
$-60,149
Davis Scott G.CEO
0
$0
1
$111,912
$-111,912

About Ekso Bionics Holdings, Inc.

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

Insider Activity of Ekso Bionics Holdings, Inc.

Over the last 12 months, insiders at Ekso Bionics Holdings, Inc. have bought $0 and sold $232,062 worth of Ekso Bionics Holdings, Inc. stock.

On average, over the past 5 years, insiders at Ekso Bionics Holdings, Inc. have bought $15,477 and sold $181,868 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,032 shares for transaction amount of $5,005 was made by Lathan Corinna (director) on 2023‑11‑02.

List of Insider Buy and Sell Transactions, Ekso Bionics Holdings, Inc.

2026-01-06SaleJones Jason CChief Operating Officer
1,320
0.0545%
$9.25
$12,210
-8.60%
2025-12-09SaleJones Jason CChief Operating Officer
270
0.01%
$4.70
$1,269
+71.37%
2025-12-09SaleWong JeromeChief Financial Officer
1,238
0.046%
$4.70
$5,819
+71.37%
2025-11-10SaleDavis Scott G.CEO
23,315
0.9138%
$4.80
$111,912
+11.20%
2025-11-10SaleJones Jason CChief Operating Officer
9,723
0.3811%
$4.80
$46,670
+11.20%
2025-11-10SaleWong JeromeChief Financial Officer
11,288
0.4424%
$4.80
$54,182
+11.20%
2023-11-02PurchaseLathan Corinnadirector
4,032
0.0281%
$1.24
$5,005
+5.65%
2023-08-23PurchaseLathan Corinnadirector
5,500
0.0402%
$0.95
$5,222
+38.73%
2023-08-17SaleDavis Scott G.President & COO
37,446
0.2868%
$1.00
$37,281
+32.32%
2023-08-17SaleWong JeromeChief Financial Officer
12,784
0.0979%
$1.00
$12,728
+32.32%
2023-08-10PurchaseLathan Corinnadirector
4,201
0.0332%
$1.25
$5,251
+11.97%
2023-05-24SaleSHERMAN STEVENExecutive Chair
45,660
0.3393%
$1.44
$65,874
-6.85%
2023-05-08SaleJones Jason CChief Operating Officer
3,435
0.0259%
$1.57
$5,401
-13.38%
2022-12-04SaleSHERMAN STEVENExecutive Chair
10,576
0.084%
$1.28
$13,492
+7.75%
2022-11-21SaleSHERMAN STEVENCEO & Chairman
5,787
0.0421%
$1.26
$7,312
+3.79%
2022-11-16SaleJones Jason CSenior VP Product Development
782
0.0059%
$1.28
$1,003
+5.43%
2022-11-16SaleWong JeromeChief Financial Officer
723
0.0055%
$1.28
$927
+5.43%
2022-10-24SaleSHERMAN STEVENCEO & Chairman
5,921
0.0449%
$1.29
$7,619
+6.98%
2022-08-31SaleJones Jason CSenior VP Product Development
5,873
0.0442%
$2.31
$13,587
-39.15%
2022-08-21SaleSHERMAN STEVENCEO & Chairman
5,572
0.0412%
$2.20
$12,278
-35.56%
Total: 49
*Gray background shows transactions not older than one year

Insider Historical Profitability

33.46%
Davis Scott G.CEO
78777
3.0041%
$777,528.9904
Jones Jason CChief Operating Officer
25621
0.977%
$252,879.2708
Wong JeromeChief Financial Officer
24771
0.9446%
$244,489.7706
Angold RussPresident, EksoWorks
391326
14.9227%
$3.86M06
SHERMAN STEVENExecutive Chair
364913
13.9155%
$3.6M112
+32.03%
Lathan Corinnadirector
147990
5.6434%
$1.46M30
+18.78%
Peurach JackChief Executive Officer
78120
2.979%
$771,044.4011
+39.84%
GLENN JOHNChief Financial Officer
35130
1.3396%
$346,733.1002
SCHEDER-BIESCHIN MAXChief Financial Officer
32371
1.2344%
$319,501.7720
+47.83%
Looby ThomasPresident & CEO
20315
0.7747%
$200,509.0520
+51.79%
Wendell Amy McBridedirector
16264
0.6202%
$160,525.6810
+39.84%
*Gray background shows insiders who have made transactions during last year

EKSO Institutional Investors: Active Positions

Increased Positions9+29.03%85,808+48.54%
Decreased Positions7-22.58%101,048-57.16%
New Positions6New82,939New
Sold Out Positions3Sold Out67,618Sold Out
Total Postitions33+6.45%161,551-8.62%

EKSO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Consolidated Portfolio Review Corp$509.002.16%64,883+64,883New2025-09-30
Citadel Advisors Llc$302.001.29%38,551+38,551New2025-09-30
Vanguard Group Inc$278.001.18%35,451+23,487+196.31%2025-09-30
Ubs Group Ag$255.001.08%32,462+32,456+540,933.33%2025-09-30
Drw Securities, Llc$158.000.67%20,189+20,189New2025-09-30
Cresset Asset Management, Llc$141.000.6%17,96400%2025-09-30
Geode Capital Management, Llc$117.000.5%14,931+2,865+23.74%2025-09-30
Shay Capital Llc$102.000.43%13,000+13,000New2025-09-30
Virtu Financial Llc$87.000.37%11,113+11,113New2025-09-30
Blackrock, Inc.$29.000.12%3,64900%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.